Company Overview
| Stock Name | Kintor Pharma-B |
|---|---|
| Stock Code | 09939 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國一家臨床階段新藥開發商,專注於自主研發潛在同類首創及同類最佳癌症藥物及其他雄激素受體相關(或AR相關)疾病藥物。 |
| Listing Date | 2020-05-22 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園C4幢401室 |
| Business Address (Hong Kong) | 香港九龍海港城港威大廈第二座20樓2007室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.kintor.com.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 20.15 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 10,075 |
| Par Value | To be extracted |
| Offer Period | 2020-05-12 to 2020-05-15 |
| Global Offering Shares | 92,347,500 shares |
| HK Public Offer Shares (Initial) | 9,235,000 shares (10.0%) |
| Public Offer Lots (Initial) | 18,470lots (Pool A9,235lots,Pool B9,235lots) |
| International Placing Shares (Initial) | 83,112,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 369,389,600 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 47.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,860,802,125 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 10,075 |
| 2 lots | 1,000 | HK$ 20,150 |
| 3 lots | 1,500 | HK$ 30,225 |
| 4 lots | 2,000 | HK$ 40,300 |
| 5 lots | 2,500 | HK$ 50,375 |
| 6 lots | 3,000 | HK$ 60,450 |
| 7 lots | 3,500 | HK$ 70,525 |
| 8 lots | 4,000 | HK$ 80,600 |
| 9 lots | 4,500 | HK$ 90,675 |
| 10 lots | 5,000 | HK$ 100,750 |
| 12 lots | 6,000 | HK$ 120,900 |
| 14 lots | 7,000 | HK$ 141,050 |
| 16 lots | 8,000 | HK$ 161,200 |
| 18 lots | 9,000 | HK$ 181,350 |
| 20 lots | 10,000 | HK$ 201,500 |
| 30 lots | 15,000 | HK$ 302,250 |
| 40 lots | 20,000 | HK$ 403,000 |
| 50 lots | 25,000 | HK$ 503,750 |
| 60 lots | 30,000 | HK$ 604,500 |
| 70 lots | 35,000 | HK$ 705,250 |
| 80 lots | 40,000 | HK$ 806,000 |
| 90 lots | 45,000 | HK$ 906,750 |
| 100 lots | 50,000 | HK$ 1,007,500 |
| 110 lots | 55,000 | HK$ 1,108,250 |
| 120 lots | 60,000 | HK$ 1,209,000 |
| 130 lots | 65,000 | HK$ 1,309,750 |
| 140 lots | 70,000 | HK$ 1,410,500 |
| 150 lots | 75,000 | HK$ 1,511,250 |
| 160 lots | 80,000 | HK$ 1,612,000 |
| 170 lots | 85,000 | HK$ 1,712,750 |
| 180 lots | 90,000 | HK$ 1,813,500 |
| 190 lots | 95,000 | HK$ 1,914,250 |
| 200 lots | 100,000 | HK$ 2,015,000 |
| 400 lots | 200,000 | HK$ 4,030,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 300,000 | HK$ 6,045,000 |
| 800 lots | 400,000 | HK$ 8,060,000 |
| 1,000 lots | 500,000 | HK$ 10,075,000 |
| 1,200 lots | 600,000 | HK$ 12,090,000 |
| 1,400 lots | 700,000 | HK$ 14,105,000 |
| 1,600 lots | 800,000 | HK$ 16,120,000 |
| 1,800 lots | 900,000 | HK$ 18,135,000 |
| 2,000 lots | 1,000,000 | HK$ 20,150,000 |
| 4,000 lots | 2,000,000 | HK$ 40,300,000 |
| 6,000 lots | 3,000,000 | HK$ 60,450,000 |
| 8,000 lots | 4,000,000 | HK$ 80,600,000 |
| 9,235 lots | 4,617,500 | HK$ 93,042,625 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 1.07B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +811% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,443,200,439 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣232.6百萬元 |
| Period-End Cash Balance | 人民幣195.5百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 698 | 0 |
| Cost of sales | -689 | 0 |
| Gross profit | 9 | 0 |
| Other income and gains, net | 12,298 | 19,018 |
| Selling and distribution expenses | 0 | -336 |
| Administrative expenses | -24,104 | -32,763 |
| Operating profit | -104,477 | -228,687 |
| Net finance costs | -4,007 | -3,890 |
| Profit before tax | -108,484 | -232,577 |
| Income tax expense | 0 | 0 |
| Profit for the year | -108,484 | -232,577 |
| Profit attributable to owners | -108,484 | -232,577 |
Balance Sheet
| Item | 2018 | 2019 |
|---|---|---|
| Cash and cash equivalents | 137,513 | 195,532 |
| Total current assets | 218,343 | 220,613 |
| Total assets | 423,597 | 553,376 |
| Total current liabilities | 108,385 | 142,583 |
| Total liabilities | 171,920 | 183,712 |
| Total equity | 251,677 | 369,664 |
| Equity attributable to owners | 251,677 | 369,664 |
| Interest-bearing borrowings | 65,000 | 58,700 |
Cash Flow Statement
| Item | 2018 | 2019 |
|---|---|---|
| Net cash from operating activities | -114,868 | -228,042 |
| Net cash from investing activities | -64,748 | -7,013 |
| Net cash from financing activities | 303,936 | 295,852 |
| Net increase in cash | 124,320 | 60,797 |
| Purchase of PP&E | -5,249 | -67,241 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 21.5 |
|---|---|
| First Day Open | HK$ 20.15 |
| First Day Change | 6.70% |
| First Day Volume | 68937600.0 |
| First Day Turnover | 1484110000.0 |
| Use of Proceeds | 1、約42%所得款項凈額(約734.0百萬港元)分配至我們的其中一種核心產品普克魯胺的開發及商業化;
2、約28%所得款項凈額(約489.3百萬港元)分配至我們的其中一種核心產品福瑞他恩的開發及商業化;
3、約4%所得款項凈額(約69.9百萬港元)分配至開發我們的臨床階段在研藥物ALK-1;
4、約4%所得款項凈額(約69.9百萬港元)分配至開發我們的臨床階段在研藥物迪拓賽替;
5、約4%所得款項凈額(約69.9百萬港元)分配至開發我們的臨床階段在研藥物GT1708F(Hedgehog/SMO抑制劑);
6、約2%所得款項凈額(約35.0百萬港元)分配至其他臨床研究項目;
7、約6%所得款項凈額(約104.8百萬港元)分配至我們臨床前階段在研藥物的研發;
8、約10%所得款項凈額(約174.7百萬港元)分配至我們的營運資金及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (3)
Joint Bookrunners (8)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
UBS Securities Hong Kong Limited CE BIN466
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
招银国际融资有限公司 CE AVM940
China Renaissance Securities (Hong Kong) Limited CE AZX839
海通国际证券有限公司 CE AAF806
建银国际金融有限公司 CE AJO225
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
Joint Lead Managers (11)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
UBS Securities Hong Kong Limited CE BIN466
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
招银国际融资有限公司 CE AVM940
China Renaissance Securities (Hong Kong) Limited CE AZX839
海通国际证券有限公司 CE AAF806
建银国际金融有限公司 CE AJO225
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
SPDB International Capital Limited CE BFZ375
富途证券国际(香港)有限公司 CE AZT137
FTFT International Securities and Futures Limited CE ATR516
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Cherry Cheeks HK Limited | 54,253,875 HKD | — | 2.92% | — | 6 months | 2020-11-22 |
| 2 | Foresight Orient Global Superior Choice SPC | 38,748,450 HKD | — | 2.08% | — | 6 months | 2020-11-22 |
| 3 | Highlight Medical Limited | 38,748,450 HKD | — | 2.08% | — | 6 months | 2020-11-22 |
| 4 | 珠海格力金融投资管理有限公司 | 759,584,475 HKD | — | 40.82% | — | 6 months | 2020-11-22 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 童友之 | — |
| Company Secretary | 陳潔、楊靜文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 童友之及郭創新為一致行動人士,通過各自全資公司KT International及KG Development分別持有緊隨全球發售完成後約27.64%及27.64%股份(假設超額配股權未獲行使)。 |
|---|




